



NEWS RELEASE

Hologic to Host Special Tomosynthesis Symposium and Feature the Latest in Women's Health Technologies at the Journées Francaises de Radiologie (JFR)

10/21/2011

New Technologies Designed to Bring Imaging Excellence, Clinical Confidence and Enhanced Patient Care to Hospitals and Imaging Centers

BEDFORD, Mass., Oct. 21, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that it will showcase its breast tomosynthesis and other new, ready-to-market technologies in women's imaging at the 59th Congress of the Journées Francaises de Radiologie (JFR) in Paris, France, October 21 to 25, 2011.

The JFR Congress provides a unique educational and training platform for reaching the European radiology community. Last year more than 18,000 people attended the Congress, many of them radiologists.

Hologic invites radiologists attending JFR to attend a special interactive Symposium titled, "Mammography and Tomosynthesis: from Screening to Intervention," to hear about the firsthand experiences of radiologists reading breast tomosynthesis cases. The Symposium will be led by three experts of breast tomosynthesis imaging:

- Dr. Pierre Gignier, Medical Imaging Center at the Hopital Prive d'Antony, France
- Dr. Anne-Pascale Schillings, Clinique du Sein, Clinique Saint-Pierre, Belgium
- Dr. Christophe Tourasse, Le Centre d'Imagerie du Sein de l'Hopital Prive Jean Mermoz a Lyon, France

The Symposium will be held on Saturday, October 22, from 12:30 to 1:30 p.m. in the Paris Palais des Congres room 252 level 2. No reservations are necessary for JFR Congress attendees.

Hologic is also showcasing a number of new products at the Congress including:



Breast Screening and Diagnostic Systems

Hologic Selenia Dimensions **breast tomosynthesis** technology is designed to help clinicians in catching breast cancers early and in significantly reducing the number of unnecessary diagnostic work-ups.

Approved by the U.S. Food and Drug Administration (FDA) in February 2011 and launched in Europe, South America, the Middle East and Asia in 2008, the Selenia Dimensions breast tomosynthesis system delivers the exceptional 2D images the industry has come to expect from Hologic and allows radiologists to offer their patients a conventional digital mammogram and a tomosynthesis exam, all in one compression, in just seconds. The combination of measurable improvements in accuracy and detection, and improved sensitivity, makes the new system a superior system compared to conventional digital mammography.

Breast Magnetic Resonance Imaging (MRI)

Hologic MRI solutions provide breakthrough technological advancements to assist in the detection and management of cancer. Hologic's breast **MRI coils** are highly sensitive for cancer staging, high risk screening, problem-solving, post treatment surveillance, and other indications. Studies show that with the appropriate MRI equipment, Breast MRI can detect many breast cancers that are often hidden when using standard imaging independent of breast size and breast density.

Breast Biopsy Solutions

With a commitment to provide patient-focused, physician-inspired clinical solutions, Hologic interventional breast solutions devices include the ATEC, Celero, and Eviva systems.

The **Eviva** system is Hologic's newest vacuum-assisted breast biopsy device designed to incorporate firing, pain management and site marking into one integrated system. Like Hologic's legacy **ATEC** system, the Eviva system is a fast, safe and simple breast biopsy device that removes suspicious breast tissue for pathological evaluation. The Eviva device is designed to deliver exceptional clinical results, while enabling physicians to treat a broader spectrum of patients. It is the only vacuum-assisted device with the **SecurMark** site marking product, Hologic's fully integrated end-deploy biopsy site marking solution made specifically for the Eviva device.

The new Hologic **Affirm** breast biopsy guidance system represents the next generation in upright breast biopsy. This innovative solution is designed for the Selenia Dimensions digital mammography system to streamline efficiency and optimize workflow, giving facilities the opportunity to offer leading edge technology in minimally invasive breast biopsy. With a quick and easy transition from mammography to upright biopsy, the system offers

practices a cost-effective, space-saving and upgradeable system to expand its range of service offerings.

Bone Health Systems

Just as Hologic is leading the way in women's health imaging solutions, the Company is raising the bar in skeletal health imaging. The Discovery bone densitometry system, Hologic's most advanced QDR series bone densitometer, offers exquisite imaging and rapid assessment of the most important risk factors for osteoporotic fracture: bone density and vertebral fracture.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Hologic, Affirm, ATEC, Celero, Dimensions, Discovery, Eviva, SecurMark and Selenia are trademarks or registered trademarks of Hologic in the United States and other countries.

Forward Looking Disclaimer

This News Release contains forward-looking information that involves known and unknown risks and uncertainties, including statements about Hologic products, including the benefits of the technologies. The Company cannot assure that the products will achieve the benefits described herein, or that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the produce can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Among other things, newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated. The risks and uncertainties included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the Company's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This press release is intended for medical professionals and/or specific product users residing in France and should

not be considered as a solicitation or promotion of any product or of an indication of any product that is not authorized by the laws and regulations of another country where the reader resides. This press release could refer to products that are or may not be available in any particular country, and/or may not have received market clearance by a governmental regulatory body for indications and restrictions in different countries.

Contact:

Caroline Cannoot
EUMENASA Marketing
Hologic, Inc.

Caroline.Cannoot@hologic.com

Tel: +32 (2) 711 46 80

Olga Karagiannis
Corporate Marketing
Hologic, Inc.

Olga.Karagiannis@hologic.com

Tel: +1 781.761.7069